JuSun It’s almost the end of the year, and is a good time to re-evaluate one’s portfolio in terms of potential winners and losers next year. With the market chasing growth stocks to nosebleed valuations, I believe better opportunities can be found to similar moat-worthy enterprises that are trading at far more reasonable valuations with a dividend kicker. This brings me to Merck (NYSE:MRK), which I last covered here in October of last year, noting the expansion of its highly profitable Keytruda drug and ...

A patient and a pharmacist talk to each other. Drazen Zigic/iStock via Getty Images It's been repeated ad nauseam, but there are no guarantees in equity investing. Even the most storied companies are susceptible to fading into the ash heap of history. At the time Lehman Brothers went bankrupt in 2008, it was in business for more than 150 years. The company established itself as the fourth-largest investment bank in the United States. High debt can only be overlooked for so long before the perfect storm brin ...

Fischerrx6 Introduction As we head into the last trading days of 2023, I wanted to cover a stock I haven't discussed before on Seeking Alpha. That company is Merck & Co. (NYSE:MRK), a drug manufacturer with a market cap of more than $270 billion. The reason why I never covered MRK is because I thought it was too boring. I was wrong. Very wrong. Over the past ten years, MRK shares have returned 215%, beating both the healthcare ETF (XLV) and the S&P 500. Data by YCharts Moreover, the stock is yielding 2. ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic ther ...

Merck & Co., Inc. (NYSE:MRK) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Development and CMO Peter Dannenbaum - Vice President, Investor Relations Analysts Umer Raffat - Evercore Umer Raffat Thank you. Listen, thank you guys for being here. Apologies. I’m a couple minutes behind. Pleasure to have Merck management join us. This is our last fireside of this conference, at least on my end. Dr. Eli ...

Merck & Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 16, 2023 5:00 AM ET Company Participants Caroline Litchfield - Chief Financial Officer Peter Dannenbaum - Head of Investor Relations Conference Call Participants Akash Tewari - Jefferies Akash Tewari All right, good morning, day three of our London Healthcare Conference. It has been a blast to see everyone here, really do appreciate it. Joining us -- and my name is Akash Tewari. I'm a pharma and biotech analyst, here at Jefferies. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 1-6571 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 22-1918501 (State or other jurisdicti ...

Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Rob Davis - Chairman and CEO Caroline Litchfield - Chief Financial Officer Dr. Dean Li - President, Merck Research Labs Conference Call Participants Chris Shibutani - Goldman Sachs Mara Goldstein - Mizuho Carter Gould - Barclays Seamus Fernandez - Guggenheim Terence Flynn - Morgan Stanley Andrew Baum - Citi Louise Chen - Cantor Chris Schott - JP ...

Merck Q3 2023 Earnings Agenda ...

Merck & Co. Inc. (NYSE:MRK) October 22, 2023 1:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dr. Dean Li - President, Merck Research Labs Eliav Barr - CMO & Head of Global Clinical Development, Merck Research Laboratories Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development Jannie Oosthuizen - President, Human Health U.S. Conference Call Participants Umer Raffat - Evercore Luisa Hector - Berenberg Trung Huynh - UBS Conor MacKay - BMO Capital Markets Louise Chen - C ...